HRTX vs. XBI
Compare and contrast key facts about Heron Therapeutics, Inc. (HRTX) and SPDR S&P Biotech ETF (XBI).
XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: HRTX or XBI.
Correlation
The correlation between HRTX and XBI is 0.37, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
HRTX vs. XBI - Performance Comparison
Key characteristics
HRTX:
-0.13
XBI:
0.40
HRTX:
0.53
XBI:
0.73
HRTX:
1.07
XBI:
1.09
HRTX:
-0.12
XBI:
0.20
HRTX:
-0.34
XBI:
1.26
HRTX:
35.28%
XBI:
8.18%
HRTX:
96.56%
XBI:
25.89%
HRTX:
-99.96%
XBI:
-63.89%
HRTX:
-99.88%
XBI:
-47.55%
Returns By Period
In the year-to-date period, HRTX achieves a -10.00% return, which is significantly lower than XBI's 2.15% return. Over the past 10 years, HRTX has underperformed XBI with an annualized return of -16.91%, while XBI has yielded a comparatively higher 3.94% annualized return.
HRTX
-10.00%
28.57%
-53.50%
-5.56%
-42.66%
-16.91%
XBI
2.15%
-2.24%
1.47%
10.34%
-1.11%
3.94%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
HRTX vs. XBI - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Heron Therapeutics, Inc. (HRTX) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
HRTX vs. XBI - Dividend Comparison
HRTX has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.14%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HRTX Heron Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.14% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% | 0.17% |
Drawdowns
HRTX vs. XBI - Drawdown Comparison
The maximum HRTX drawdown since its inception was -99.96%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for HRTX and XBI. For additional features, visit the drawdowns tool.
Volatility
HRTX vs. XBI - Volatility Comparison
Heron Therapeutics, Inc. (HRTX) has a higher volatility of 38.30% compared to SPDR S&P Biotech ETF (XBI) at 7.87%. This indicates that HRTX's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.